| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
LENSAR, Inc.
13D/A
LNSR · 52634L108
|
55.9% |
3/25/2025
Event 3/23/2025
|
||||
| North Run Capital, LP | 9.3% | |||||
| North Run Advisors, LLC | 9.3% | |||||
| NR-GRI Partners, LP | 51.1% | |||||
| NR-GRI Partners GP, LP | 51.1% | |||||
| Ellis Thomas B | 55.9% | |||||
| Hammer Todd B | 55.9% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
TELA Bio, Inc.
13G/A
TELA · 872381108
|
7.8% |
11/13/2026
Event 9/30/2026
|
||||
| North Run Capital, LP | 7.8% | |||||
| North Run Advisors, LLC | 7.8% | |||||
| North Run - Due North Partners, LP | 7.8% | |||||
| North Run GP, LP | 7.8% | |||||
| Todd B. Hammer | 7.8% | |||||
| Thomas B. Ellis | 7.8% | |||||
| Michael Bosco | 7.8% | |||||
|
Scientific Industries, Inc.
13G/A
SCND · 808757108
|
10.0% |
11/13/2025
Event 9/30/2025
|
||||
| North Run Capital, LP | 10.0% | |||||
| North Run Advisors, LLC | 10.0% | |||||
| Todd B. Hammer | 10.0% | |||||
| Thomas B. Ellis | 10.0% | |||||
| Michael Bosco | 10.0% | |||||
| North Run - Due North Partners, LP | 10.0% | |||||
| North Run GP, LP | 10.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.